April 2026
Depression
What April 2026's 25 new studies found, synthesized from the papers below. All Depression research →
The synthesis
Synthesized from 25 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Depression, major depressive disorder, MDD, depressive disorder, treatment-resistant depression, then ranked by relevance.
Research published in April 2026 on depression focused heavily on rapid-acting and novel treatments, particularly ketamine/esketamine and psychedelics, alongside meditation-based interventions. Evidence for psilocybin-assisted therapy was mixed: one meta-analysis found a large effect but low certainty, while another found no significant overall effect, highlighting context-dependence. Ketamine/esketamine consistently showed rapid antidepressant effects across various populations, though durability and comparative effectiveness varied. Overall, findings are preliminary, with significant methodological limitations and a need for larger, rigorous trials.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| The Effects of Body Scan Meditation on Depression, Anxiety, Stress, and Impulsivity among Alcohol-Related Offenders 2026 | RCT | 30 | Supports | Body scan meditation significantly reduced depression, anxiety, stress, and impulsivity and improved interoceptive awareness compared to control. |
| Pharmacological augmentation in treatment-resistant depression: a neurobiologically informed, practical decision guide for treatment choice with lithium, quetiapine, or esketamine. 2026 | narrative review | Unclear | Argues that lithium, quetiapine, and esketamine differ in profile but converge on neuroplasticity pathways, yet validated predictive markers for differential response are lacking. | |
| From synapse to strategy: a bibliometric map of ionotropic glutamate receptors in depression. 2026 | bibliometric analysis | 6843 | Unclear | Mapped research evolution showing a shift from basic synaptic mechanisms to clinical innovations, with NMDA receptors and treatment-resistant depression as primary hotspots. |
| Baseline EEG Temporal Dynamics as a Thalamic Filter State Biomarker: A Thalamic Filter Model Account of Ketamine Antidepressant Response Prediction and Depression as Thalamic Over-Filtering 2026 | review | Supports | Argues that baseline EEG features indicating higher thalamic filter impedance predict better antidepressant response to ketamine, proposing the Thalamic Filter Model. | |
| Repeated intranasal esketamine augmentation in treatment-resistant obsessive-compulsive disorder with comorbid major depressive disorder: a prospective case series. 2026 | case series | 8 | Supports | Intranasal esketamine substantially improved depressive symptoms (MADRS decreased 48.8%) and modestly reduced OCD symptoms (Y-BOCS decreased 30.3%). |
| Media hype regarding psychedelic treatments for depression and PTSD from 2017 to 2024 2026 | pre-registered analysis of media coverage | 6805 | Mixed | Media coverage of psychedelics used more positive emotion and sentiment language, while antidepressants had more negative emotion and risk language; reward language was more associated with antidepressants. |
| Treatment of major depressive disorder and treatment resistant depression with 5-MeO-DMT: Impact of 25 years of non-traditional public scientific communication and education on clinical development and commercialization 2026 | review | Unclear | Argues that informal use of 5-MeO-DMT has generated knowledge about alleviating depressive symptoms, but communication gaps hinder integration into mainstream psychiatry. | |
| Characterising the clinical associations of hallucinogen persisting perception disorder: a retrospective cohort study 2026 | retrospective cohort study | 25778 | Unclear | Found high rates of depressive episodes (29.2%) and anxiety disorders (26.2%) in HPPD patients, with anxiety and post-viral fatigue predicting HPPD development. |
| Preliminary evidence that serum interleukin-6 is a candidate biomarker of response to esketamine in treatment-resistant depression. 2026 | open-label phase 2 trial | 14 | Supports | Higher baseline IL-6 levels predicted more rapid symptom reduction with esketamine, while lower IL-6 predicted greater symptom severity and disability. |
| The Monoamine-Glutamate Continuum of Depression: A Neurobiological Framework for Precision Psychiatry. 2026 | narrative review | Unclear | Argues that depressive syndromes reflect varying contributions of monoaminergic and glutamatergic-neuroplastic impairment, proposing a 'monoamine-glutamate continuum' framework. | |
| Ayahuasca Therapy: Possible Reduction of Suicidal Ideation in Treatment-Resistant Depression - A Systematic Review. 2026 | systematic review | 5 | Supports | Ayahuasca administration was associated with rapid and significant reductions in suicidal ideation and depressive symptoms across five studies. |
| Efficacy and Safety of Psilocybin-Assisted Therapy for Depression: A Meta-Analysis of Randomised Controlled Trials 2026 | systematic review and meta-analysis | 514 | Supports | Psilocybin-assisted therapy showed a large pooled effect on depressive symptom reduction (SMD=1.270), but evidence was rated low certainty due to methodological limitations. |
| Esketamine-sufentanil PCA reduces postoperative depression state in elderly colorectal cancer patients: a randomized controlled trial. 2026 | RCT | 99 | Supports | Low-dose esketamine (1 mg/kg) adjunct to sufentanil PCA significantly reduced postoperative depression and anxiety without enhancing analgesia or increasing adverse events. |
| Neuroscientific Basis of Ketamine as an Analgesic and Emerging Role in the Management of Depression. 2026 | narrative review | Supports | Ketamine and esketamine demonstrated rapid antidepressant effects in MDD and TRD, but heterogeneity in dosing and limited long-term data restrict definitive recommendations. | |
| The efficacy and safety of psilocybin-assisted therapy for major depressive disorder: a meta-analytic review of clinical outcomes 2026 | systematic review and meta-analysis | 606 | No effect | Psilocybin-assisted psychotherapy showed no statistically significant overall antidepressant effect (SMD=-0.79, p=0.63), with extreme heterogeneity and context-dependent efficacy. |
| REDUCTION IN SYMPTOMS OF POSTTRAUMATIC STRESS DISORDER AND DEPRESSION IN UKRAINIAN REFUGEES PRACTICING TRANSCENDENTAL MEDITATION 2026 | controlled trial | 80 | Supports | Transcendental Meditation practice significantly reduced PTSD and depression symptoms, with probable PTSD decreasing from 60% to 2.5% after 30 days. |
| Longitudinal Effects of Mindfulness Combined with Gratitude Touch on Anxiety, Depression, and Stress: A 12-Month Portable EEG-Based Study. 2026 | longitudinal study | Supports | Combining mindfulness with gratitude touch reduced anxiety, depression, and stress over 12 months. | |
| Psilocybin reshapes cortical inhibition through selective interneuron recruitment. 2026 | experimental study | Unclear | Psilocybin reduced firing of somatostatin-expressing interneurons and increased activity of parvalbumin-expressing interneurons via 5-HT1A receptor, altering cortical inhibition. | |
| Ketamine Use in Critically Ill Patients: Insights into Depressive Symptoms and Hemodynamic Changes. 2026 | retrospective study | 34 | Supports | Subanesthetic ketamine improved apparent and reported sadness in ICU patients without significant hemodynamic instability. |
| Innovative Approaches to Depression Therapy: The Antidepressant Efficacy and Mechanisms of General Anesthetics. 2026 | review | Supports | Several general anesthetics, including ketamine, propofol, isoflurane, and specific opioids, exhibit rapid and sustained antidepressant effects via modulation of glutamate and GABA signals. | |
| Comparison of average time-to-relapse following ECT versus ketamine - A systematic review. 2026 | systematic review | 13 | Mixed | Both ECT and ketamine showed sustained therapeutic potential, with ECT possibly associated with longer remission, but no direct comparisons of time-to-relapse were available. |
| A systematic review of ketamine and esketamine-induced long-term potentiation and synaptic scaling: Do the molecular and synaptic plasticity effects inform dosing intervals? 2026 | systematic review | 78 | Supports | Ketamine may open a plasticity window lasting approximately 2-3 days, and dosing intervals aligned with this window may optimize antidepressant durability. |
| Study 29296 | review | Supports | Psilocybin may offer therapeutic benefits for inflammation-driven disorders of aging, such as depression, by modulating inflammatory pathways and promoting neuroplasticity. | |
| Comparison of rTMS and esketamine for treatment-resistant depression: A target trial emulation. 2026 | observational cohort | 3380 | Mixed | rTMS was associated with lower risk of hospitalization, arrhythmia, and injury compared to esketamine, while suicide-related outcomes were broadly comparable except for a protective effect of esketamine during 30-90 days. |
| Filtering the noise: a cerebellar-centered framework for understanding and treating mental illness -a paradigm shift in psychiatry 2026 | theoretical or philosophical paper | Unclear | Argues that psychiatric conditions stem from breakdowns in sensory filtering mechanisms, with the cerebellum as a critical hub, and that psychedelics may recalibrate these filters. |
Body scan meditation significantly reduced depression, anxiety, stress, and impulsivity and improved interoceptive awareness compared to control.
RCT Sample size: 30
Argues that lithium, quetiapine, and esketamine differ in profile but converge on neuroplasticity pathways, yet validated predictive markers for differential response are lacking.
narrative review
Mapped research evolution showing a shift from basic synaptic mechanisms to clinical innovations, with NMDA receptors and treatment-resistant depression as primary hotspots.
bibliometric analysis Sample size: 6843
Argues that baseline EEG features indicating higher thalamic filter impedance predict better antidepressant response to ketamine, proposing the Thalamic Filter Model.
review
Intranasal esketamine substantially improved depressive symptoms (MADRS decreased 48.8%) and modestly reduced OCD symptoms (Y-BOCS decreased 30.3%).
case series Sample size: 8
Media coverage of psychedelics used more positive emotion and sentiment language, while antidepressants had more negative emotion and risk language; reward language was more associated with antidepressants.
pre-registered analysis of media coverage Sample size: 6805
Argues that informal use of 5-MeO-DMT has generated knowledge about alleviating depressive symptoms, but communication gaps hinder integration into mainstream psychiatry.
review
Found high rates of depressive episodes (29.2%) and anxiety disorders (26.2%) in HPPD patients, with anxiety and post-viral fatigue predicting HPPD development.
retrospective cohort study Sample size: 25778
Higher baseline IL-6 levels predicted more rapid symptom reduction with esketamine, while lower IL-6 predicted greater symptom severity and disability.
open-label phase 2 trial Sample size: 14
Argues that depressive syndromes reflect varying contributions of monoaminergic and glutamatergic-neuroplastic impairment, proposing a 'monoamine-glutamate continuum' framework.
narrative review
Ayahuasca administration was associated with rapid and significant reductions in suicidal ideation and depressive symptoms across five studies.
systematic review Sample size: 5
Psilocybin-assisted therapy showed a large pooled effect on depressive symptom reduction (SMD=1.270), but evidence was rated low certainty due to methodological limitations.
systematic review and meta-analysis Sample size: 514
Low-dose esketamine (1 mg/kg) adjunct to sufentanil PCA significantly reduced postoperative depression and anxiety without enhancing analgesia or increasing adverse events.
RCT Sample size: 99
Ketamine and esketamine demonstrated rapid antidepressant effects in MDD and TRD, but heterogeneity in dosing and limited long-term data restrict definitive recommendations.
narrative review
Psilocybin-assisted psychotherapy showed no statistically significant overall antidepressant effect (SMD=-0.79, p=0.63), with extreme heterogeneity and context-dependent efficacy.
systematic review and meta-analysis Sample size: 606
Transcendental Meditation practice significantly reduced PTSD and depression symptoms, with probable PTSD decreasing from 60% to 2.5% after 30 days.
controlled trial Sample size: 80
Combining mindfulness with gratitude touch reduced anxiety, depression, and stress over 12 months.
longitudinal study
Psilocybin reduced firing of somatostatin-expressing interneurons and increased activity of parvalbumin-expressing interneurons via 5-HT1A receptor, altering cortical inhibition.
experimental study
Subanesthetic ketamine improved apparent and reported sadness in ICU patients without significant hemodynamic instability.
retrospective study Sample size: 34
Several general anesthetics, including ketamine, propofol, isoflurane, and specific opioids, exhibit rapid and sustained antidepressant effects via modulation of glutamate and GABA signals.
review
Both ECT and ketamine showed sustained therapeutic potential, with ECT possibly associated with longer remission, but no direct comparisons of time-to-relapse were available.
systematic review Sample size: 13
Ketamine may open a plasticity window lasting approximately 2-3 days, and dosing intervals aligned with this window may optimize antidepressant durability.
systematic review Sample size: 78
Psilocybin may offer therapeutic benefits for inflammation-driven disorders of aging, such as depression, by modulating inflammatory pathways and promoting neuroplasticity.
review
rTMS was associated with lower risk of hospitalization, arrhythmia, and injury compared to esketamine, while suicide-related outcomes were broadly comparable except for a protective effect of esketamine during 30-90 days.
observational cohort Sample size: 3380
Argues that psychiatric conditions stem from breakdowns in sensory filtering mechanisms, with the cerebellum as a critical hub, and that psychedelics may recalibrate these filters.
theoretical or philosophical paper
Points of agreement
- Ketamine and esketamine consistently show rapid antidepressant effects across various populations, including TRD, postoperative, and ICU settings.
- Psilocybin-assisted therapy shows large effect sizes in some meta-analyses but is heavily qualified by methodological limitations and context-dependence.
- Meditation-based interventions (body scan, transcendental meditation, mindfulness) show significant reductions in depressive symptoms.
- Several reviews converge on the importance of glutamatergic and neuroplasticity mechanisms in depression treatment.
Conflicts
- Meta-analyses of psilocybin-assisted therapy conflict: one found a large significant effect (SMD=1.270) while another found no significant overall effect (SMD=-0.79).
- Comparative effectiveness of rTMS vs esketamine shows mixed results: rTMS had better safety outcomes but esketamine had a protective effect on suicide in certain intervals.
- Media coverage analysis found reward language more associated with antidepressants, contrary to expectations of psychedelic hype.
Gaps
- Durability of antidepressant effects beyond short-term follow-up is largely unstudied.
- Blinding is compromised in psychedelic trials due to subjective effects, affecting validity.
- Most studies have small sample sizes and lack diverse populations.
- Validated predictive biomarkers for differential treatment response are lacking.
- Long-term safety and optimal dosing intervals for ketamine and psychedelics remain unclear.